A cost-benefit analysis of lipid standardization in the United States

Preventing Chronic Disease

Volumn 8, Issue 6, 2011, Pages

  Hoerger, Thomas J ^a   Wittenborn, John S ^a   Young, Walter ^b  

^a RTI INTERNATIONAL   (United States)

^b National Association of Chronic Disease Directors   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE QUALITY; HUMAN; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY; STANDARD; STATISTICAL MODEL; UNITED STATES;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COST-BENEFIT ANALYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LOGISTIC MODELS; MIDDLE AGED; PROGRAM EVALUATION; QUALITY-ADJUSTED LIFE YEARS; REFERENCE STANDARDS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84857469870     PISSN: 15451151     EISSN: 21665435     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Adult Treatment Panel III (ATP III). The third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Bethesda (MD): National Heart Lung and Blood Institute, National Institutes of Health; 2002. NIH publication no. 02-5215.
2. Death rates from heart disease by selected characteristics. The 2009 statistical abstract: the national data book, from Table 112: age-adjusted death rates by major causes: 1960 to 2005. US Census Bureau; 2009. http://www.census.gov/prod/2008pubs/09statab/vitstat.pdf. Accessed June 27, 2011.
3. Heron MP, Hoyert DL, Murphy SL, Xu JQ, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep 2009;57(14):1-134.
4. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med 2007;356(23):2388-98.
5. Capewell S, Hayes DK, Ford ES, Critchley JA, Croft JB, Greenlund KJ, et al. Life-years gained among US adults from modern treatments and changes in the prevalence of 6 coronary heart disease risk factors between 1980 and 2000. Am J Epidemiol 2009;170(2):229-36.
6. Myers GL, Cooper GR, Winn CL. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med 1989;9(1):105-35.
7. Kimberly MM, Caudill SP, Cooper GR, Dasti M, Monsell E, Myers GL, et al. CDC's Lipid Standardization Program: assuring quality in epidemiologic studies for 50 years. J Clin Lipidol 2008;2(3):222.
8. Myers GL, Kimberly MM, Waymack PP, Smith SJ, Cooper GR, Sampson EJ. A Reference Method Laboratory Network for Cholesterol: a model for standardization and improvement of clinical laboratory measurements. Clin Chem 2000;46(11):1762-72.
9. Thienpont LM, Van Landuyt KG, Stöckl D, De Leenheer AP. Four frequently used test systems for serum cholesterol evaluated by isotope dilution gas chromatography-mass spectrometry candidate reference method. Clin Chem 1996;42(4):531-5.
10. Wholey JS. Evaluation - promise and performance. Washington (DC): Urban Institute; 1979.
11. Current status of blood cholesterol measurement in clinical laboratories in the United States: a report from the Laboratory Standardization Panel of the National Cholesterol Education Program. Clin Chem 1988;34(1):193-201.
12. Stein EA, Myers GL. National Cholesterol Education Program recommendations for triglyceride measurement: executive summary. Clin Chem 1995;41(10):1421-6.
13. Warnick GR, Wood PD. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. Clin Chem 1995;41(10):1427-33.
14. Cleeman JI, Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, et al. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
15. Grosse SD. Assessing cost-effectiveness in healthcare:history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8(2):165-78.
16. Braithwaite RS, Meltzer DO, King JT, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46(4):349-56.
17. Dockins C, Maguire K, Simon N, Sullivan M. Value of statistical life analysis and environmental policy: a white paper. Washington (DC): US Environmental Protection Agency, National Center for Environmental Economics; 2004.
18. Murphy KM, Topel RH. The value of health and longevity. Cambridge (MA): National Bureau of Economic Research; 2005. Working Paper 11405.
19. Gallaher MP, Mobley LR, Klee GG, Schryver P. The impact of calibration error in medical decision making. Research Triangle Park (NC): RTI International; 2004. http://www.rti.org/pubs/Calibration_Error.pdf. Accessed June 16, 2011.